Return to homepagePandemic Pact

Bundibugyo Ebolavirus Vaccine Candidate Using ChAdOx1 Platform

  • Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:0 publications
Grant search

Key facts

  • Disease

    Ebola

  • Start & end year

    2026

  • Known Financial Commitments (USD)

    $0

  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)

  • Principal Investigator

    N/A

  • Research Location

    Congo (DRC), Uganda

  • Lead Research Institution

    University of Oxford

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

CEPI committed initial funding of up to US$8.6 million to support preclinical testing and development activities for a Bundibugyo ebolavirus vaccine candidate based on the University of Oxford's ChAdOx1 platform. Funding will support creation of a Master Virus Seed stock and manufacture of clinical-grade doses by the Serum Institute of India. The programme seeks to rapidly prepare the vaccine candidate for Phase 1 clinical trials.